Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α.
James N IngleJunmei CairnsVera J SumanLois E ShepherdPeter Andreas FaschingTanya L HoskinRavinder J SinghZeruesenay DestaKrishna R KalariMatthew J EllisPaul E GossBingshu E ChenBernhard VolzPoulami BarmanErin E CarlsonTufia HaddadMatthew P GoetzBarbara GoodnatureMatthew E CuellarMichael A WaltersCristina CorreiaScott H KaufmannRichard M WeinshilboumLiewei WangPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
This matched case-control clinical study revealed that levels of estrone and estradiol above identified thresholds after 6 months of adjuvant anastrozole treatment were associated with increased risk of an EBCE. Preclinical laboratory studies revealed that anastrozole, but not exemestane or letrozole, is a ligand for ERα. These findings represent potential steps towards individualized anastrozole therapy.